These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33206282)

  • 21. Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.
    Park S; Jung JA; Ju S; Lim HS
    Front Pharmacol; 2023; 14():1288308. PubMed ID: 38293674
    [No Abstract]   [Full Text] [Related]  

  • 22. SB3 (Ontruzant
    Lamb YN
    BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars.
    Díaz LP; Millán S; Chaban N; Campo AD; Spitzer E
    Future Oncol; 2021 Jul; 17(19):2529-2544. PubMed ID: 33904318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
    Trukhin D; Poddubskaya E; Andric Z; Makharadze T; Bellala RS; Charoentum C; Yañez Ruiz EP; Fulop A; Hyder Ali IA; Syrigos K; Katgi N; Lopez Chuken YA; Rumyana I; Reyes-Igama J; Costamilan RC; Del Campo García A; Florez A; Paravisini A; Millan S;
    BioDrugs; 2021 Jul; 35(4):429-444. PubMed ID: 33914256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
    Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
    Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
    Syrigos K; Abert I; Andric Z; Bondarenko IN; Dvorkin M; Galic K; Galiulin R; Kuchava V; Sriuranpong V; Trukhin D; Zhavrid E; Fu D; Kassalow LM; Jones S; Bashir Z;
    BioDrugs; 2021 Jul; 35(4):417-428. PubMed ID: 34264503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of bevacizumab biosimilar on wound healing complications in patients with colorectal cancer undergoing endoscopic mucosal resection: A systematic review and meta-analysis in anorectal medicine.
    Li Y; Mei Z; Shi L; Wan Y; Zhou X; Zeng T; Liu Y; Yang JY; Shi Z
    Int Wound J; 2024 Jan; 21(1):e14638. PubMed ID: 38272807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA's Approval of the First Biosimilar to Bevacizumab.
    Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PB006: A Natalizumab Biosimilar.
    Shirley M
    Clin Drug Investig; 2024 May; 44(5):367-370. PubMed ID: 38683493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
    Stroyakovskiy DL; Fadeeva NV; Matrosova MP; Shelepen KG; Adamchuk GA; Roy B; Nagarkar R; Kalloli M; Zhuravleva D; Voevodin GD; Shustova MS; Kryukov F
    BMC Cancer; 2022 Feb; 22(1):129. PubMed ID: 35105329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT-P10 (Truxima™): A Rituximab Biosimilar.
    Deeks ED
    BioDrugs; 2017 Jun; 31(3):275-278. PubMed ID: 28497220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Prospective, Randomized, Multiple-Dose, Multi-Center, Comparative Clinical Study to Evaluate the Efficacy, Safety, Immunogenicity of a biosimilar Bevacizumab (Test product, Hetero) and Reference Medicinal Product (Bevacizumab, Roche) in Patients of Metastatic Colorectal Cancer.
    Advani S; Biswas G; Sinha S; B B; Bandi VK; Naidu N; Thakur P; Chary S
    J Assoc Physicians India; 2018 Jun; 66(6):55-59. PubMed ID: 31331137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
    Thatcher N; Goldschmidt JH; Thomas M; Schenker M; Pan Z; Paz-Ares Rodriguez L; Breder V; Ostoros G; Hanes V
    Clin Cancer Res; 2019 Apr; 25(7):2088-2095. PubMed ID: 30617139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study.
    Qin S; Li J; Bai Y; Shu Y; Li W; Yin X; Cheng Y; Sun G; Deng Y; Zhong H; Li Y; Qian X; Zhang L; Zhang J; Chen K; Kang W;
    BioDrugs; 2021 Jul; 35(4):445-458. PubMed ID: 34014555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men.
    Markus R; Chow V; Pan Z; Hanes V
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):755-763. PubMed ID: 28864922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer.
    Rhodes W; DeClue RW; Accortt NA; Jin R; Sandschafer D; Wertz D; Patel K
    Future Oncol; 2021 Dec; 17(36):5119-5127. PubMed ID: 34698523
    [No Abstract]   [Full Text] [Related]  

  • 39. Sample Size for Biosimilar Trials: In Defense of Synthesis.
    Clark T; Jo SJ; Phillips A
    Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
    Knight B; Rassam D; Liao S; Ewesuedo R
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.